U.S. drug manufacturer AbbVie’s $63 billion partnership with Allergan is getting support from Nestle and AstraZeneca buying up products the Irish-domiciled firm is shedding to placate regulators.
AbbVie is engulfing Allergan to give it control of the profitable wrinkle remedy Botox and to diversify a portfolio heavily depending on its $19-billion-per-year arthritis drug Humira, the world’s best-selling medication that’s advancing toward U.S. patent expiration.
Swiss food company Nestle bulked up its medical nutrition enterprise with Allergan’s Zenpep, a product with 2018 sales of $237 million, which treats people whose pancreases don’t provide sufficient enzymes to digest fats, proteins, and sugars.
Nestle didn’t give financial particulars; however, analysts from Zuercher Kantonalbank estimated the takeover might have cost the Vevey, Switzerland-based mostly firm over $1 billion.
In the meantime, AstraZeneca is regaining rights to brazikumab, Allergan’s experimental drug towards Crohn’s Disease and ulcerative colitis. The European Commission stated this month the immunology drugs have to be divested because of the chance its growth would be stopped after AbbVie’s takeover due to competing medicines.
With regulators wary of the agreement’s anti-competitive potential, competitors are getting an opportunity to stock their own product cabinets.
Nestle CEO Mark Schneider, who further gets Allergan’s Viokace, another pancreatic enzyme product, in Monday’s agreement, is stacking up on diet products that combine properties of drugs and food as the Swiss organization expands in areas where development may outpace its mainstream food enterprise.
AstraZeneca’s agreement for
brazikumab underlines a return of the inflammation drugs to the British drug manufacturer’s portfolio.